Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Drago, Joshua Z; Lawrence, Donald; Livingstone, Elisabeth; Zimmer, Lisa; Chen, Tianqi; Giobbie-Hurder, Anita; Amann, Valerie C; Mangana, Joanna; Siano, Marco; Zippelius, Alfred; Dummer, Reinhard; Goldinger, Simone M; Sullivan, Ryan J (2019). Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma research, 29(1):65-69.

Moreira, Alvaro; Loquai, Carmen; Pföhler, Claudia; Kähler, Katharina C; Knauss, Samuel; Heppt, Markus V; Gutzmer, Ralf; Dimitriou, Florentia; Meier, Friedegund; Mitzel-Rink, Heidrun; Schuler, Gerold; Terheyden, Patrick; Thoms, Kai-Martin; Türk, Matthias; Dummer, Reinhard; Zimmer, Lisa; Schröder, Rolf; Heinzerling, Lucie (2018). Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. European Journal of Cancer, 106:12-23.

Zimmer, Lisa; Apuri, Susmitha; Eroglu, Zeynep; Kottschade, Lisa A; Forschner, Andrea; Gutzmer, Ralf; Schlaak, Max; Heinzerling, Lucie; Krackhardt, Angela M; Loquai, Carmen; Markovic, Svetomir N; Joseph, Richard W; Markey, Kelly; Utikal, Jochen S; Weishaupt, Carsten; Goldinger, Simone M; Sondak, Vernon K; Zager, Jonathan S; Schadendorf, Dirk; Khushalani, Nikhil I (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 75:47-55.

Zimmer, Lisa; Goldinger, Simone M; Hofmann, Lars; Loquai, Carmen; Ugurel, Selma; Thomas, Ioannis; Schmidgen, Maria I; Gutzmer, Ralf; Utikal, Jochen S; Göppner, Daniela; Hassel, Jessica C; Meier, Friedegund; Tietze, Julia K; Forschner, Andrea; Weishaupt, Carsten; Leverkus, Martin; Wahl, Renate; Dietrich, Ursula; Garbe, Claus; Kirchberger, Michael C; Eigentler, Thomas; Berking, Carola; Gesierich, Anja; Krackhardt, Angela M; Schadendorf, Dirk; Schuler, Gerold; Dummer, Reinhard; Heinzerling, Lucie M (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60:210-225.

Van Allen, Eliezer M; Miao, Diana; Schilling, Bastian; Shukla, Sachet A; Blank, Christian; Zimmer, Lisa; Sucker, Antje; Hillen, Uwe; Geukes Foppen, Marnix H; Goldinger, Simone M; Utikal, Jochen; Hassel, Jessica C; Weide, Benjamin; Kaehler, Katharina C; Loquai, Carmen; Mohr, Peter; Gutzmer, Ralf; Dummer, Reinhard; Gabriel, Stacey; Wu, Catherine J; Schadendorf, Dirk; Garraway, Levi A (2015). Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science, 350(6257):207-211.

Van Allen, Eliezer M; Wagle, Nikhil; Sucker, Antje; Treacy, Daniel J; Johannessen, Cory M; Goetz, Eva M; Place, Chelsea S; Taylor-Weiner, Amaro; Whittaker, Steven; Kryukov, Gregory V; Hodis, Eran; Rosenberg, Mara; McKenna, Aaron; Cibulskis, Kristian; Farlow, Deborah; Zimmer, Lisa; Hillen, Uwe; Gutzmer, Ralf; Goldinger, Simone M; Ugurel, Selma; Gogas, Helen J; Egberts, Friederike; Berking, Carola; Trefzer, Uwe; Loquai, Carmen; Weide, Benjamin; Hassel, Jessica C; Gabriel, Stacey B; Carter, Scott L; Getz, Gad; Garraway, Levi A; Schadendorf, Dirk (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1):94-109.

Goldinger, Simone M; Zimmer, Lisa; Schulz, Carsten; Ugurel, Selma; Hoeller, Christoph; Kaehler, Katharina C; Schadendorf, Dirk; Hassel, Jessica C; Becker, Juergen; Hauschild, Axel; Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50(2):406-410.

Zimmer, Lisa; Hillen, Uwe; Livingstone, Elisabeth; Lacouture, Mario E; Busam, Klaus; Carvajal, Richard D; Egberts, Friederike; Hauschild, Axel; Kashani-Sabet, Mohammed; Goldinger, Simone M; Dummer, Reinhard; Long, Georgina V; McArthur, Grant; Scherag, André; Sucker, Antje; Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30(19):2375-2383.

This list was generated on Wed Jun 19 20:08:40 2019 CEST.